Yong Yu - 21 Nov 2023 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
VP, Clinical Trial Operations
Signature
/s/ Sean Ryder, Attorney-in-Fact
Issuer symbol
GNLX
Transactions as of
21 Nov 2023
Transactions value $
-$191,555
Form type
4
Date filed
22 Nov 2023, 16:15
Previous filing
21 Nov 2023
Next filing
08 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNLX Common Stock Sale -$192K -18.7K -21.21% $10.26 69.3K 21 Nov 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average sale price for the transaction reported was $10.2628, and the range of prices were between $9.91 and $10.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.